We are live on ! Find out more
ALSV

ATP Life Science Ventures Portfolio holdings

AUM $898M
1-Year Est. Return 84.86%
This Fund
S&P 500
This Quarter Est. Return
+69.09%
1 Year Est. Return
+84.86%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$553M
Cap. Flow
+$78M
Cap. Flow %
6.02%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$60.8M
2
STOK icon
Stoke Therapeutics
STOK
+$17.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
1
Stoke Therapeutics
STOK
$1.82B
$1.06B 82.06%
17,161,713
+375,000
+2% +$17.2M
AKRO
2
DELISTED
Akero Therapeutics
AKRO
$168M 13.01%
5,830,203
– –
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$63.9M 4.93%
+4,028,937
New +$60.8M

Similar funds

TNB
TCF National Bank Sioux Falls, South Dakota $883M AUM 60.21% 1-Year Est. Return
FIB
First Interstate Bancsystem Billings, Montana $841M AUM
NAM
North American Management Boston, Massachusetts $738M AUM 49.23% 1-Year Est. Return
SGMP
Spark Growth Management Partners Boston, Massachusetts $591M AUM
FBP
Flippin Bruce & Porter Lynchburg, Virginia $553M AUM 70.43% 1-Year Est. Return
PA
Paracle Advisors Mercer Island, Washington $551M AUM 50.34% 1-Year Est. Return
AAM
Anglepoint Asset Management George Town, Cayman Islands $1.28B AUM 131.9% 1-Year Est. Return
PPCM
Pillar Pacific Capital Management Pacifica, California $1.29B AUM 80.18% 1-Year Est. Return

ATP Life Science Ventures's Q4 2020 Portfolio in Review

As of Q4 2020, ATP Life Science Ventures held 3 positions worth $1.3B, up 75% from $742M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ATP Life Science Ventures deployed $78M of net new capital in Q4 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 4,028,937 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ATP Life Science Ventures's largest Q4 2020 buy was Chinook Therapeutics, Inc. Common Stock: 4,028,937 shares worth $63.9M.
  • ATP Life Science Ventures added most to Stoke Therapeutics in Q4 2020, an estimated $17.2M increase.
  • ATP Life Science Ventures's ten largest holdings make up 100% of its $1.3B portfolio in Q4 2020.
  • ATP Life Science Ventures opened 1 new position and closed 0 in Q4 2020.
  • ATP Life Science Ventures's portfolio value rose 75% quarter-over-quarter to $1.3B.

Based on ATP Life Science Ventures's 13F filing for Q4 2020, filed 3 Feb 2021.